

selpercatinib hard capsules (Retsevmo®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2732	as monotherapy for the treatment of adults and adolescents 12 years and older with advanced rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC). SMC restriction: patients who require systemic therapy and have not previously received systemic therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	09/06/2025	10/08/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9192/selpercatinib-retsevmo-final-may-2025-amended-040625-for-website.pdf				
durvalumab concentrate for solution for infusion (Imfinzi®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2735	In combination with tremelimumab for the first-line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).	Not routinely available as not recommended for use in NHS Scotland	09/06/2025	21/05/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9197/durvalumab-imfinzi-final-may-2025-amended-090625-for-website.pdf				

New Medicines Decisions for June 2025

bempedoic acid film-coated tablets (Nilemdo®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2740	in adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: <ul style="list-style-type: none"> • in patients on a maximum tolerated dose of a statin with or without ezetimibe or, • alone or in combination with ezetimibe in patients who are statin-intolerant, or for whom a statin is contraindicated 	Not routinely available as not recommended for use in NHS Scotland	09/06/2025	21/05/2025
Other Decision Specified : Non-submission				
Web Link : https://scottishmedicines.org.uk/media/9194/bempedoic-acid-nilemdo-non-sub-final-may-2025-for-website.pdf				

New Medicines Decisions for June 2025

bempedoic acid / ezetimibe film-coated tablets (Nustendi®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2741	in adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: <ul style="list-style-type: none"> • in patients on a maximum tolerated dose of a statin and not adequately controlled with additional ezetimibe treatment or, • in patients who are either statin-intolerant, or for whom a statin is contraindicated, and not adequately controlled with ezetimibe treatment or, • in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets. 	Not routinely available as not recommended for use in NHS Scotland	09/06/2025	21/05/2025
Other Decision Specified : Non-submission				
Web Link : https://scottishmedicines.org.uk/media/9185/bempedoic-acid_ezetimibe-nustendi-non-sub-final-may-2025-for-website.pdf				
bevacizumab gamma (Lytenava®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2744	in adults for treatment of neovascular (wet) age-related macular degeneration (nAMD).	Not routinely available as there is a local preference for alternative medicines	09/06/2025	17/09/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9196/bevacizumab-gamma-lytenava-abb-final-april-2025-amended-280525-for-website.pdf				

ruxolitinib tablets (Jakavi®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2750	for the treatment of patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	09/06/2025	10/08/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9191/ruxolitinib-jakavi-final-may-2025-for-website.pdf				
cladribine tablet (Mavenclad®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2751	for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease as defined by clinical or imaging features. SMC restriction: for use in patients with active relapsing-remitting multiple sclerosis (RRMS)	Available in line with national guidance	09/06/2025	10/08/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9187/cladribine-mavenclad-final-may-2025-amended-040625-for-website.pdf				

New Medicines Decisions for June 2025

sumatriptan 85mg / naproxen 457mg (Suvexx®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2756	the acute treatment of the headache phase of migraine attacks with or without aura in adults where treatment with a mono-entity product has been insufficient.	Not routinely available as not recommended for use in NHS Scotland	09/06/2025	21/05/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9193/sumatriptan-naproxen-suvexx-abb-final-may-2025-for-website.pdf				
pegylated liposomal irinotecan (Onivyde®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2812	in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.	Not routinely available as not recommended for use in NHS Scotland	09/06/2025	21/05/2025
Other Decision Specified : Non-submission				
Web Link : https://scottishmedicines.org.uk/media/9189/pegylated-liposomal-irinotecan-onivyde-non-sub-final-may-2025-for-website.pdf				

New Medicines Decisions for June 2025

pegzilarginase solution for injection/infusion (Loargys®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2813	treatment of arginase 1 deficiency (ARG1-D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older	Not routinely available as not recommended for use in NHS Scotland	09/06/2025	
Other Decision Specified : Non-submission				
Web Link : https://scottishmedicines.org.uk/media/9190/pegzilarginase-loargys-non-sub-final-may-2025-for-website.pdf				